Products under development
LFB’s 10% immunoglobulin is registered for the treatment of rare immune system conditions in 15 European countries. Registration is also pending in several other countries around the world. Within Europe, its registration also includes the treatment of a rare neurological condition: Multifocal Motor Neuropathy.
A recombinant “anti-D” monoclonal antibody, for the prevention of certain allo immunisation situations, is currently under Phase IIb clinical development and is slated for European registration.
The U.S. Biologics License Application (BLA) for LFB’s recombinant activated Factor VII is currently being reviewed by the FDA. LFB’s rFVIIa is potentially indicated for the treatment of haemophilia.
The LFB’s Von Willebrand Factor recombinant, already being marketed in several countries, is currently in the advanced stages of development and involves two new indications, for European registration.
LFB’s fibrinogen has been registered in 16 European countries since early 2018: it is indicated for very rare coagulopathies, in both children and adults. Registration is also pending in several other countries around the world.